Objective:To investigate whether the biomarker of uCTX-Ⅱ has a diagnostic and prognostic value in the early stage osteoarthritis or not. Methods:Forty patients with clinical diagnosis of early stage knee osteoarthritis and 35 patients with progression stage osteoarthritis were randomly assigned to receive 1 500 mg of glucosamine daily,100 mg of diacerein daily or both glucosamine and diacerein. Disease symptoms were assessed quarterly by WOMAC scoring. X-ray analysis was performed as baseline. uCTX-Ⅱ level in urinary were measured as a baseline,6 months,12 months after the initiation of the intervention. The parameters were also corrected for creatinine treatment. Results:A clinically detectable symptomatic benefit was observed as early as 3 months in all groups. In the combined group and the diacerein group,the WOMAC scores decreased singnificantly than that of the glucosamine goup(P < 0.05). The CTX-Ⅱ levels measured in early stage osteoarthritis was significantly higher in urine samples than that from the healthy controls(P < 0.05). A correlation was seen between the uCTX-Ⅱ levers and the WOMAC scores using bivariate analysis. Conclusion:The biomarker of uCTX-Ⅱhad diagnostic and prognostic value in the early stage oteoarthritis. Glucosamine and diacerein alone or combination could reduce pain effectively in the all groups of patients. The combination of glucosamine and diacerein may be more effective.